Antisense-Mediated APP Suppression as Potential Therapeutic for Down Syndrome Alzheimer's Disease

This study investigates antisense oligonucleotides designed to reduce amyloid precursor protein (APP) expression, which is elevated in Down syndrome due to trisomy 21 and contributes to early-onset Alzheimer's disease. The approach represents a targeted molecular intervention strategy to address a key genetic driver of neurodegeneration in this population.